CORM-401 |
Catalog No.GC34893
One-Click Copy Product Info
|
CORM-401 is a manganese-containing carbon monoxide-releasing molecule. CORM-401 can release CO in the presence of oxidants to exert anti-inflammatory and antioxidant stress effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1001015-18-4
Sample solution is provided at 25 µL, 10mM.
CORM-401 is a manganese-containing carbon monoxide-releasing molecule. CORM-401 can release CO in the presence of oxidants to exert anti-inflammatory and antioxidant stress effects. CORM-401 regulates cellular metabolism by uncoupling mitochondrial respiration and inhibiting glycolysis. CORM-401 can be used in research on ischemia-reperfusion injury, inflammatory diseases, metabolic diseases, and periodontitis[1-4].
In vitro, BV2 cells were treated with 5-500µM CORM-401 for 0-400 minutes. Low concentrations (5µM, 10µM) increased oxygen consumption rate and maintained ATP levels. Concentrations of 50µM and above first briefly stimulated and then inhibited respiration and reduced ATP. CORM-401 uncoupled the mitochondrial respiratory chain[5]. A549 cells were treated with mitochondria-targeted nanoparticles CORM-TPP@HA containing CORM-401 (5-40µg/mL) for 24 hours. The treatment inhibited A549 cell viability, elevated mitochondrial ROS, intracellular copper, and cuproptosis-related proteins ATOX1, ATP7A, and COX17[6]. EA.hy926 cells were treated with 30-100µM CORM-401 for 1 hour. The treatment induced NO production, increased NADPH concentration, accelerated the pentose phosphate pathway, and reduced the ratio of reduced to oxidized glutathione (GSH/GSSG)[7].
In vivo, C57BL/6 mice with high-fat diet-induced obesity were intragastrically administered 30mg/kg CORM-401 three times per week for 14 weeks. CORM-401 reduced body weight gain, lowered fasting blood glucose and insulin levels, and improved HOMA-IR[8]. Healthy control mice and sickle cell disease (SS) mice were orally given 30mg/kg CORM-401 three times per week for 3 weeks. CORM-401 increased blood carboxyhemoglobin levels and hepatic carbon monoxide accumulation, reduced inflammatory cell infiltration, thrombosis, and iron deposition in the lungs, liver, and kidneys of SS mice, decreased pulmonary macrophage iron accumulation, reduced plasma white blood cell counts in SS mice, and alleviated the rise in blood urea nitrogen[9]. Male C57BL/6J mice fed a high-fat diet were intragastrically administered 30mg/kg CORM-401 three times per week for 7 weeks. CORM-401 reduced body weight and white adipose tissue mass, decreased adipocyte size, lowered triglyceride content in white adipose tissue, and reduced hepatic fat accumulation[10].
References:
[1] Bauer N, Yuan Z, Yang X, et al. Plight of CORMs: The unreliability of four commercially available CO-releasing molecules, CORM-2, CORM-3, CORM-A1, and CORM-401, in studying CO biology. Biochem Pharmacol. 2023 Aug;214:115642.
[2] Chen Y, Chen H, Li Z. Multifunctional peptide-drug conjugate CORM-401@R9: A novel approach to combat oxidative stress in cataracts. Free Radic Biol Med. 2025 Feb 1;227:570-581.
[3] Bauer N, Mao Q, Vashistha A, et al. Compelling Evidence: A Critical Update on the Therapeutic Potential of Carbon Monoxide. Med Res Rev. 2025 Jul;45(4):1275-1301.
[4] Yao S, Wang Y, Shao L, et al. Injured renal cell membrane encapsulated ICG/CORM-401 for homologous targeted NIR theranostics of acute kidney injury. Journal of Nanobiotechnology. 2025 Aug 26;23:589.
[5] Wilson JL, Bouillaud F, Almeida AS, et al. Carbon monoxide reverses the metabolic adaptation of microglia cells to an inflammatory stimulus. Free Radic Biol Med. 2017;104:226-242.
[6] Shao L, Song Z, Gong X, et al. Mitochondria-targeted CORM-401 nanoparticles inhibit A549 cells by triggering cuproptosis. BMC Biotechnol. 2026;26(64).
[7] Kaczara P, Proniewski B, Lovejoy C, et al. CORM-401 induces calcium signalling, NO increase and activation of pentose phosphate pathway in endothelial cells. FEBS J. 2018;285(7):1346-58.
[8] Braud L, Pini M, Muchova L, et al. Carbon monoxide-induced metabolic switch in adipocytes improves insulin resistance in obese mice. JCI Insight. 2018 Nov 15;3(22):e123485.
[9] Nguyen KA, Matte A, Foresti R, et al. An oral carbon monoxide-releasing molecule protects against acute hyperhemolysis in sickle cell disease. Blood. 2024 Jun 13;143(24):2544-58.
[10] Klemola E, Posio K, Karpale M, et al. Carbon monoxide-releasing molecule CORM-401 treatment elicits corticosterone-driven stress lipolysis and tissue-specific hypoxia-inducible factor activation. Redox Biology. 2026;95:104295.
| Cell experiment [1]: | |
|
Cell lines |
EA.hy926 cells (human endothelial cell line) |
|
Preparation Method |
EA.hy926 cells were maintained in DMEM supplemented with 10% FBS, 1g/L glucose, 110mg/L sodium pyruvate, 2mM GlutaMAX, 100IU penicillin, 100μg/mL streptomycin and 2% HAT supplement at 37°C, 5% CO2. EA.hy926 cells were treated with CORM-401 at 30μM or 100μM for 1 hour, then assessed for NO production by EPR spectroscopy, cytosolic calcium concentration by fura-2/fluo-4 fluorescence microscopy, and intracellular metabolite levels by LC-MS/MS-based metabolomics. |
|
Reaction Conditions |
30μM or 100μM; 1h |
|
Applications |
CORM-401 induced NO production, elicited peak-like and slow gradual cytosolic calcium increases, accelerated pentose phosphate pathway with elevated NADPH concentration, and decreased the GSH/GSSG ratio in EA.hy926 cells. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
Male C57BL/6 mice were fed a high-fat diet (HFD) for 14 weeks and orally gavaged with CORM-401 (30mg/kg) 3 times per week; mice were sacrificed after a 6-hour fast and 48 hours after the last CORM-401 administration for collection of blood, epididymal white adipose tissue (eWAT), brown adipose tissue (BAT), and liver, with assessment of glucose/insulin tolerance tests, COHb and tissue CO levels, Akt phosphorylation by Western blot, OCR/ECAR in eWAT by Seahorse analyzer, and metabolic gene expression by qPCR. |
|
Dosage form |
30mg/kg; p.o.; 3 times/week for 14 weeks |
|
Applications |
CORM-401 reduced body weight gain and plasma leptin, lowered fasting blood glucose and insulin with improved HOMA-IR, enhanced insulin-induced systemic insulin sensitivity and Akt phosphorylation in eWAT, increased CO content in eWAT, reduced adipocyte size and macrophage infiltration in eWAT, decreased IL-6/IL-1β/IL-10 and Hmox-1 expression in eWAT, restored PPar-γ/adiponectin/Fabp4/Hsl/Glut4/Irs1/Hk2/Vegf mRNA in eWAT, reduced BAT weight and lipid content with restored PPar-γ/Vegf/adiponectin/Pgc1-α/Ucp1 mRNA, increased ECAR and lactate in eWAT, and did not alter liver weight, lipid content, or plasma liver injury markers. |
References: [1] Kaczara P, Proniewski B, Lovejoy C, et al. CORM-401 induces calcium signalling, NO increase and activation of pentose phosphate pathway in endothelial cells. FEBS J. 2018 Apr;285(7):1346-58. [2] Braud L, Pini M, Muchova L, et al. Carbon monoxide-induced metabolic switch in adipocytes improves insulin resistance in obese mice. JCI Insight. 2018 Nov 15;3(22):e123485. | |
| Cas No. | 1001015-18-4 | SDF | |
| Canonical SMILES | O#C[Mn+]1(C#O)(C#O)([SH-]C(N(C)CC([O-])=O)=S1)C#O.[H+] | ||
| Formula | C8H8MnNO6S2 | M.Wt | 331.2 |
| Solubility | DMSO : 25 mg/mL (Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0193 mL | 15.0966 mL | 30.1932 mL |
| 5 mM | 603.9 μL | 3.0193 mL | 6.0386 mL |
| 10 mM | 301.9 μL | 1.5097 mL | 3.0193 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)